...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Evaluating the Effect of Cabergoline on Glycaemic Control of Patients with Type 2 Diabetes Mellitus: A Randomised Controlled Trial
【24h】

Evaluating the Effect of Cabergoline on Glycaemic Control of Patients with Type 2 Diabetes Mellitus: A Randomised Controlled Trial

机译：评估冰箱对2型糖尿病患者血糖控制的影响：随机对照试验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Although bromocriptine has been approved as an antidiabetic agent, few studies have reported the beneficial effects of other anti-hyperglycemic long acting dopamine agonist agents. In this regard, Cabergoline has fewer side-effects than that of Bromocriptine which can be administered as one or two days per week with higher compliance rates in patients.Aim: To determine the effect of Cabergoline on glycaemic control in patients with Type 2 Diabetes Mellitus (DM).Materials and Methods: In this double-blind clinical trial, initial laboratory parameters including Fasting Plasma Glucose (FBS), 2 Hours Postprandial Plasma Glucose (2HPPG), HbA1c, Total Cholesterol (T-Chol), Triglycerides (TG), and High Density Lipoproteins (HDL) were assessed. The subjects were randomly assigned into two case and control groups. The intervention group received 0.25 mg Cabergoline tablets weekly for the first 2 weeks and 0.5 mg per week for the next 12 weeks. Control group also received placebo tablets. All clinical and laboratory assessments were repeated 3 months after initial visit. Paired t-test, independent t-test and chi-square were used for the comparison of quantitative and qualitative variables, respectively. Covariance analysis was also used to adjust for confounding variables. p<0.05 was considered as statistically significant.Results: HbA1c (p=0.01) and TG (0.04) levels were significantly decreased after intervention in the case group compared to the controls.Conclusion: Cabergoline, over a 3 months period, exhibits beneficial effects on HbA1C and TG levels and may possibly be useful as a long-term anti-diabetic drug in patients with type 2 DM.
机译：虽然溴隐亭已被批准为抗糖尿病剂，但是少数研究报告了其他抗高血糖长效的多巴胺激动剂剂的有益效果。在这方面，Cabergoline的副作用比溴杉木的副作用较少，所述溴杉木可以作为每周一种或两天施用患者的依从性率较高。目的：确定Cabergoline对类型患者血糖控制的影响2糖尿病（DM）。材料和方法：在这种双盲临床试验中，初始实验室参数包括空腹血浆葡萄糖（FBS），2小时餐后血浆葡萄糖（2HPPG），HBA1C，总胆固醇（T-氯），评估甘油三酯（Tg）和高密度脂蛋白（HDL）。将受试者随机分配到两种情况和对照组。干预组每周收到0.25毫克Cabergoline片剂，每周2周，每周每周0.5毫克。对照组还接受了安慰剂片。初次访问后3个月重复所有临床和实验室评估。配对T检验，独立的T检验和Chi-Square分别用于比较定量和定性变量。协方差分析也用于调整混淆变量。 P <0.05被认为是统计学意义。结果：在案例组的干预与对照组中，在案例组的干预后，HBA1C（P = 0.01）和TG（0.04）水平显着降低。结论：Cabergoline，超过3几个月的时间，对HBA1C和TG水平表现出有益的影响，并且可能是2 DM型患者的长期抗糖尿病药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号